Nicox
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1996-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.nicox.com
Clinical Trials
15
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
ADenoVirus Initiative Study in Epidemiology in Italy
- Conditions
- Viral Conjunctivitis
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- NicOx
- Target Recruit Count
- 241
- Registration Number
- NCT03055065
- Locations
- 🇮🇹
Clinica oculistica / Ospedale san Paolo, Milano, Italy
Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)
- Conditions
- Adenoviral Conjunctivitis
- Interventions
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- NicOx
- Registration Number
- NCT03009799
- Locations
- 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
ADenoVirus Initiative Study in Epidemiology in Spain
- Conditions
- Viral Conjunctivitis
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- NicOx
- Target Recruit Count
- 386
- Registration Number
- NCT02254330
- Locations
- 🇪🇸
VISSUM, Alicante, Spain
🇪🇸Clinica Barraquer, Barcelona, Spain
🇪🇸Hospital Clinic, Barcelona, Spain
ADenoVirus Initiative Study in Epidemiology in UK
- Conditions
- Viral Conjunctivitis
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- NicOx
- Target Recruit Count
- 31
- Registration Number
- NCT02112773
- Locations
- 🇬🇧
Queen Alexandra Hospital, Portsmouth, United Kingdom
ADenoVirus Initiative Study in Epidemiology in Germany
- Conditions
- Viral Conjunctivitis
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- NicOx
- Target Recruit Count
- 240
- Registration Number
- NCT02054273
- Locations
- 🇩🇪
Uwe Pleyer, Berlin, Germany
🇩🇪University eye hospital Freiburg, Freiburg, Germany
🇩🇪Florian Seidensticker, Hannover, Germany
- Prev
- 1
- 2
- 3
- Next
News
Pipeline Analysis Reveals 20+ Therapies in Development for Open-Angle Glaucoma Treatment
DelveInsight's latest report identifies 18+ companies developing 20+ therapeutic candidates for open-angle glaucoma, with several treatments advancing through late-stage clinical trials.
NCX 470 Shows Superior IOP Control Over Latanoprost in Mont Blanc Trial Analysis
New analysis from Mont Blanc Phase 3 trial reveals NCX 470 enabled more patients to achieve target intraocular pressure of ≤18 mmHg compared to standard-of-care latanoprost.
Ocular Hypertension: Over 60 Companies Advance Clinical Trial Pipeline
The ocular hypertension market is expanding due to increased prevalence of conditions affecting aqueous humor outflow, leading to elevated intraocular pressure (IOP).
Nicox's NCX 470 Phase 3 Glaucoma Trial Fully Enrolled in China Ahead of Schedule
Nicox SA announced its Denali Phase 3 trial of NCX 470 for open-angle glaucoma or ocular hypertension is fully enrolled in China, accelerating the overall trial timeline.
Nicox Secures $16.5 Million Financing to Advance NCX 470 Glaucoma Trial
Nicox has entered a $16.5 million financing agreement with Soleus, combining royalty sales and equity financing to fund operations into Q3 2025.
Nicox's ZERVIATE Approved in China for Allergic Conjunctivitis
Ocumension Therapeutics, Nicox's partner, has received approval in China to commercialize ZERVIATE for treating ocular itching linked to allergic conjunctivitis.
Nicox Completes U.S. Recruitment for Phase 3 Glaucoma Trial of NCX 470
Nicox has completed recruitment and randomization of the final patient in the United States for its Denali Phase 3 trial evaluating NCX 470, a novel NO-donating bimatoprost eye drop for open-angle glaucoma and ocular hypertension.